The Effect of an Anti-inflammatory Diet in Patients With Rheumatoid Arthritis

Rheumatoid Arthritis Clinical Trial

— DAIAR  

Official title:

The Effect of an Anti-inflammatory Diet on Disease Activity and Quality of Life in Patients With Rheumatoid Arthritis - Parallel Controlled Randomized Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05336513
• Other study ID #: DAIAR
• Status: Completed
• Phase: N/A
• Start date: April 1, 2021
• Est. completion date: December 20, 2021

Study information

• Verified date: April 2022
• Source: Universidade Nova de Lisboa
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Rheumatoid arthritis (RA) is an autoimmune disease that affects 0.5-1% of the population and in which his remission is not always achieved, affecting physical and mental well-being and quality of life (QL). As a complement to pharmacotherapy, dietary intervention should be evaluated as a treatment option.

The main objective of this parallel controlled randomized clinical trial is to check the effect of an anti-inflammatory dietary intervention, compared to a diet based on the principles of the Mediterranean diet (control), on disease activity (AD) and improving QL.

Patients will be instructed to follow an anti-inflammatory diet (DAI) or a control diet (DC) for 6 months. The AD and QL will be evaluated at the end of the intervention.

As there are no dietary guidelines for RA, this study aims to provide scientific evidence about the impact of diet therapy on reducing AD and improving QL.

Description:

The main objective of this trial is to check the effect of an DAI, compared to a DC, on reducing AD and improving QL.

As secondary objectives, it is intended to investigate the relationship of DAI with inflammatory markers and with the modulation of the composition / diversity of the intestinal microbiota, in comparison with a DC.

This study combines all dietary components with an anti-inflammatory effect, thus allowing the possibility of evaluating the full potential of dietary treatment in the disease, including intestinal microbiota modulation.

These results are intended to further contribute to clinical decision making and better evidence-based treatment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 26
• Est. completion date: December 20, 2021
• Est. primary completion date: December 20, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age over 18 years;

• Presence of active disease, (DAS28= 2.6), under adequate control and medication.

• Able to sign informed consent

Exclusion Criteria:

• Any type of psychological deficiency, dementia or eating disorder;

• Presence of food allergies and / or intolerances;

• Be vegetarian or use Phytotherapy or other supplements (namely, pre and probiotics);

• Use of antibiotics im the last 6 months;

• Have had previous nutritional monitoring or change in eating habits in the last 6 months.

Related Conditions & MeSH terms

• Arthritis
• Arthritis, Rheumatoid
• Rheumatoid Arthritis

Intervention

Other:
• Diet Control
Diet following mediterranean principles, for 15 weeks
• Diet anti-inflammatory
Diet combining food items with anti-inflammatory potential, following the principles described in Rondanelli, Clinical Nutrition, 2021 Mar;40(3):661-689. doi: 10.1016/j.clnu.2020.08.020.

Locations

Country	Name	City	State
Portugal	Hospital Particular do Algarve - HPA Saúde	Portimão

Sponsors (2)

Lead Sponsor	Collaborator
Universidade Nova de Lisboa	Hospital Particular do Algarve - HPA Saúde

Country where clinical trial is conducted

Portugal, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes in disease activity	Difference between the intervention and control group in the changes in Disease Activity (using DAS28 score: greater than 2,6 implies active disease), from baseline to the end of follow-up	15 weeks
Primary	Changes in Quality of Life	Difference between the intervention and control group in changes in Quality of Life (Health Assessment Questionnaire (HAQ): scores of 0 to 1 are generally considered to represent mild to moderate difficulty, 1 to 2 moderate to severe disability, and 2 to 3 severe to very severe disability), from baseline to the end of follow-up	15 weeks
Secondary	Changes in C-Reactive Protein (CRP)	Difference between the intervention and control group in changes in C-Reactive Protein (CRP) measured in mg/L, from baseline to the end of follow-up	15 weeks
Secondary	Changes in Erythrocyte Sedimentation Rate (ESR)	Difference between the intervention and control group in changes in Erythrocyte Sedimentation Rate (ESR) measured in mm/h, from baseline to the end of follow-up	15 weeks
Secondary	Changes in Rheumatoid Factor (RF)	Difference between the intervention and control group changes in Rheumatoid Factor (RF) measured in IU/mL, from baseline to the end of follow-up	15 weeks
Secondary	Changes in Gut microbiota	Difference between the intervention and control group in the change of gut microbiota from baseline to the end of follow-up.; Bacterial DNA will be extracted from fecal samples. 16SRNA gene will be sequenced by next-generation sequencing (NGS). All the identified bacterial phyla, genus and species will be expressed in percentage.	15 weeks
Secondary	Changes in weight	Difference between the intervention and control group changes in weight, measured in Kg, from baseline to the end of follow-up	15 weeks
Secondary	Changes in Body Mass Index (BMI)	Difference between the intervention and control group changes in BMI, calculated using weight and height, presented in kg/m2: underweight < 18,5; normoweight 18,6-24,9; overweight 25-29,9; obese >30, from baseline to the end of follow-up	15 weeks
Secondary	Changes in waist circumference perimeter	Difference between the intervention and control group changes in waist circumference perimeter, measured in cm, from baseline to the end of follow-up	15 weeks